Literature DB >> 32231504

Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620.

Michael Untch1, Sibylle Loibl2, Peter A Fasching3.   

Abstract

Entities:  

Year:  2019        PMID： 32231504      PMCID： PMC7098310          DOI： 10.1159/000500624

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  24 in total

1.  How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?

Authors:  Sibylle Loibl; Carsten Denkert
Journal:  J Clin Oncol       Date:  2017-01-30       Impact factor: 44.544

2.  Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.

Authors:  Shannon K Swisher; Jose Vila; Susan L Tucker; Isabelle Bedrosian; Simona F Shaitelman; Jennifer K Litton; Benjamin D Smith; Abigail S Caudle; Henry M Kuerer; Elizabeth A Mittendorf
Journal:  Ann Surg Oncol       Date:  2015-10-28       Impact factor: 5.344

3.  Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Miguel Martin; Frankie A Holmes; Bent Ejlertsen; Suzette Delaloge; Beverly Moy; Hiroji Iwata; Gunter von Minckwitz; Stephen K L Chia; Janine Mansi; Carlos H Barrios; Michael Gnant; Zorica Tomašević; Neelima Denduluri; Robert Šeparović; Erhan Gokmen; Anna Bashford; Manuel Ruiz Borrego; Sung-Bae Kim; Erik Hugger Jakobsen; Audrone Ciceniene; Kenichi Inoue; Friedrich Overkamp; Joan B Heijns; Anne C Armstrong; John S Link; Anil Abraham Joy; Richard Bryce; Alvin Wong; Susan Moran; Bin Yao; Feng Xu; Alan Auerbach; Marc Buyse; Arlene Chan
Journal:  Lancet Oncol       Date:  2017-11-13       Impact factor: 41.316

4.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

Authors:  B Fisher; A Brown; E Mamounas; S Wieand; A Robidoux; R G Margolese; A B Cruz; E R Fisher; D L Wickerham; N Wolmark; A DeCillis; J L Hoehn; A W Lees; N V Dimitrov
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

5.  Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.

Authors:  Michael Untch; Christian Jackisch; Andreas Schneeweiss; Bettina Conrad; Bahriye Aktas; Carsten Denkert; Holger Eidtmann; Hermann Wiebringhaus; Sherko Kümmel; Jörn Hilfrich; Mathias Warm; Stefan Paepke; Marianne Just; Claus Hanusch; John Hackmann; Jens-Uwe Blohmer; Michael Clemens; Silvia Darb-Esfahani; Wolfgang Daniel Schmitt; Serban Dan Costa; Bernd Gerber; Knut Engels; Valentina Nekljudova; Sibylle Loibl; Gunter von Minckwitz
Journal:  Lancet Oncol       Date:  2016-02-08       Impact factor: 41.316

6.  Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Authors:  Michael Untch; Peter A Fasching; Gottfried E Konecny; Stephan Hasmüller; Annette Lebeau; Rolf Kreienberg; Oumar Camara; Volkmar Müller; Andreas du Bois; Thorsten Kühn; Elmar Stickeler; Nadia Harbeck; Cornelia Höss; Steffen Kahlert; Thomas Beck; Werner Fett; Keyur M Mehta; Gunter von Minckwitz; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

Review 7.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321

8.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

Authors:  Norikazu Masuda; Soo-Jung Lee; Shoichiro Ohtani; Young-Hyuck Im; Eun-Sook Lee; Isao Yokota; Katsumasa Kuroi; Seock-Ah Im; Byeong-Woo Park; Sung-Bae Kim; Yasuhiro Yanagita; Shinji Ohno; Shintaro Takao; Kenjiro Aogi; Hiroji Iwata; Joon Jeong; Aeree Kim; Kyong-Hwa Park; Hironobu Sasano; Yasuo Ohashi; Masakazu Toi
Journal:  N Engl J Med       Date:  2017-06-01       Impact factor: 91.245

9.  Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.

Authors:  Abigail S Caudle; Wei T Yang; Savitri Krishnamurthy; Elizabeth A Mittendorf; Dalliah M Black; Michael Z Gilcrease; Isabelle Bedrosian; Brian P Hobbs; Sarah M DeSnyder; Rosa F Hwang; Beatriz E Adrada; Simona F Shaitelman; Mariana Chavez-MacGregor; Benjamin D Smith; Rosalind P Candelaria; Gildy V Babiera; Basak E Dogan; Lumarie Santiago; Kelly K Hunt; Henry M Kuerer
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

10.  Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Chiun-Sheng Huang; Max S Mano; Sibylle Loibl; Eleftherios P Mamounas; Michael Untch; Norman Wolmark; Priya Rastogi; Andreas Schneeweiss; Andres Redondo; Hans H Fischer; William Jacot; Alison K Conlin; Claudia Arce-Salinas; Irene L Wapnir; Christian Jackisch; Michael P DiGiovanna; Peter A Fasching; John P Crown; Pia Wülfing; Zhimin Shao; Elena Rota Caremoli; Haiyan Wu; Lisa H Lam; David Tesarowski; Melanie Smitt; Hannah Douthwaite; Stina M Singel; Charles E Geyer
Journal:  N Engl J Med       Date:  2018-12-05       Impact factor: 176.079
View more
  1 in total

1.  Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624].

Authors:  Mircea Dediu; Christoph Zielinski
Journal:  Breast Care (Basel)       Date:  2019-08-29       Impact factor: 2.860
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.